Loading...
Idelalisib for the treatment of non-Hodgkin lymphoma
INTRODUCTION: B-cell Non-Hodgkin lymphomas (B-NHLs) include a number of disease subtypes, each defined by the tempo of disease progression and the identity of the cancerous cell. Idelalisib is a potent, selective inhibitor of the delta isoform of phosphatidylinositol-3-kinase (PI3K), a lipid kinase...
Na minha lista:
| Udgivet i: | Expert Opin Pharmacother |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4955805/ https://ncbi.nlm.nih.gov/pubmed/26818003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14656566.2016.1135130 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|